ACADIA Pharmaceuticals Inc. (ACAD)
After hours:
- GuruFocus.com
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.
- Business Wire
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
SAN DIEGO, April 02, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
- Business Wire
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 01, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.
